Joinn Labs undermined by AI as FDA phases out animal drug testing
The outsourced clinical research services provider’s shares tumbled after the U.S. drug regulator announced a new approach to drug testing Key Takeaways: Joinn Labs’ shares fell on heavy trading as…
Recent Articles
Joinn Labs undermined by AI as FDA phases out animal drug testing
6127.HK
603127.SHG
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- As Covid drug cash dwindles, Vigonvita targets new remedies
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
